BIOLASE (BIOL) Stock Forecast, Price & News

2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for BIOLASE in the last year. There are currently 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" BIOL shares.
View BIOL analyst ratings or view top-rated stocks.

2 brokerages have issued twelve-month price objectives for BIOLASE's stock. Their BIOL share price forecasts range from $1.50 to $14.00. On average, they predict the company's stock price to reach $5.63 in the next twelve months. This suggests a possible upside of 7,111.5% from the stock's current price.
View analysts price targets for BIOL or view top-rated stocks among Wall Street analysts.

BIOLASE's stock was trading at $0.65 at the start of the year. Since then, BIOL stock has decreased by 88.0% and is now trading at $0.0780.
View the best growth stocks for 2023 here.

The company is scheduled to release its next quarterly earnings announcement on Thursday, August 10th 2023.
View our BIOL earnings forecast.

BIOLASE, Inc. (NASDAQ:BIOL) posted its quarterly earnings data on Tuesday, March, 28th. The medical technology company reported ($1.28) earnings per share for the quarter. The medical technology company had revenue of $14.05 million for the quarter. BIOLASE had a negative net margin of 60.92% and a negative trailing twelve-month return on equity of 244.91%.

BIOLASE's stock reverse split on the morning of Friday, April 29th 2022. The 1-25 reverse split was announced on Friday, April 29th 2022. The number of shares owned by shareholders was adjusted after the market closes on Friday, April 29th 2022. An investor that had 100 shares of stock prior to the reverse split would have 4 shares after the split.

BIOLASE updated its FY 2023 earnings guidance on Friday, May, 26th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $60.58M-, compared to the consensus revenue estimate of $59.91 million.

4 employees have rated BIOLASE Chief Executive Officer John R. Beaver on Glassdoor.com. John R. Beaver has an approval rating of 13% among the company's employees. This puts John R. Beaver in the bottom 10% of approval ratings compared to other CEOs of publicly-traded companies. 35.0% of employees surveyed would recommend working at BIOLASE to a friend.

Based on aggregate information from My MarketBeat watchlists, some companies that other BIOLASE investors own include Himax Technologies (HIMX), Accelerate Diagnostics (AXDX), Biocept (BIOC), Magnachip Semiconductor (MX), Fluidigm (FLDM), Matinas BioPharma (MTNB), MicroVision (MVIS), Acasti Pharma (ACST), Bionano Genomics (BNGO) and Genius Brands International (GNUS).

BIOLASE trades on the NASDAQ under the ticker symbol "BIOL."

BIOLASE's stock is owned by many different institutional and retail investors. Top institutional investors include Perkins Capital Management Inc. (10.34%) and Renaissance Technologies LLC (0.53%). Insiders that own company stock include Education Foundation Schuler, John R Beaver, John R Beaver, Jonathan T Md Lord and Larry N Feinberg.
View institutional ownership trends.

Shares of BIOL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of BIOL stock can currently be purchased for approximately $0.08.

BIOLASE (NASDAQ:BIOL) has a market capitalization of $2.44 million and generates $48.46 million in revenue each year. The medical technology company earns $-28,630,000.00 in net income (profit) each year or ($3.47) on an earnings per share basis.

The company employs 158 workers across the globe.

BIOLASE's mailing address is 27042 Towne Center Drive Suite 270, Lake Forest CA, 92610. The official website for the company is www.biolase.com. The medical technology company can be reached via phone at (949) 361-1200, via email at rcaron@dresnerallencaron.com, or via fax at 949-273-6677.